中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
20期
44-45,46
,共3页
重组人血管内皮抑制素%培美曲塞%非小细胞肺癌%临床疗效
重組人血管內皮抑製素%培美麯塞%非小細胞肺癌%臨床療效
중조인혈관내피억제소%배미곡새%비소세포폐암%림상료효
recombinant human endostatin%pemetrexed%non-small-cell lung cancer%clinical efficacy
目的：观察重组人血管内皮抑制素联合培美曲塞治疗中晚期非小细胞肺癌的临床疗效。方法选择医院收治的中晚期非小细胞肺癌患者68例，随机分为对照组和观察组，各34例。两组患者均给予培美曲塞化学治疗(简称化疗)，观察组患者在此基础上同步给予重组人血管内皮抑制素，3周为1个疗程，两组均治疗2个疗程。在治疗过程中，可根据患者治疗反应给予相应支持治疗。结果治疗后，观察组近期疗效为67．64％，显著高于对照组的50．00％（P＜0．05）。治疗结束后，两组患者卡氏生活质量评分(KPS评分)均较治疗前有所下降，但观察组下降程度更小（P＜0．05）；治疗结束1个月后，两组患者 KPS 评分均较治疗前有所升高，且观察组改善程度更优（P＜0．05）。治疗后，观察组患者的中位进展时间、中位生存期及1年生存率均显著高于对照组（P＜0．05）。两组患者总不良反应发生率比较，差异无统计学意义（P＞0．05）。结论重组人血管内皮抑制素联合培美曲塞治疗中晚期非小细胞肺癌的近期疗效较好，可显著提高患者生存质量，延迟中位进展时间，提高中位生存期及1年生存率，且未显著增加不良反应发生率，值得临床推广。
目的：觀察重組人血管內皮抑製素聯閤培美麯塞治療中晚期非小細胞肺癌的臨床療效。方法選擇醫院收治的中晚期非小細胞肺癌患者68例，隨機分為對照組和觀察組，各34例。兩組患者均給予培美麯塞化學治療(簡稱化療)，觀察組患者在此基礎上同步給予重組人血管內皮抑製素，3週為1箇療程，兩組均治療2箇療程。在治療過程中，可根據患者治療反應給予相應支持治療。結果治療後，觀察組近期療效為67．64％，顯著高于對照組的50．00％（P＜0．05）。治療結束後，兩組患者卡氏生活質量評分(KPS評分)均較治療前有所下降，但觀察組下降程度更小（P＜0．05）；治療結束1箇月後，兩組患者 KPS 評分均較治療前有所升高，且觀察組改善程度更優（P＜0．05）。治療後，觀察組患者的中位進展時間、中位生存期及1年生存率均顯著高于對照組（P＜0．05）。兩組患者總不良反應髮生率比較，差異無統計學意義（P＞0．05）。結論重組人血管內皮抑製素聯閤培美麯塞治療中晚期非小細胞肺癌的近期療效較好，可顯著提高患者生存質量，延遲中位進展時間，提高中位生存期及1年生存率，且未顯著增加不良反應髮生率，值得臨床推廣。
목적：관찰중조인혈관내피억제소연합배미곡새치료중만기비소세포폐암적림상료효。방법선택의원수치적중만기비소세포폐암환자68례，수궤분위대조조화관찰조，각34례。량조환자균급여배미곡새화학치료(간칭화료)，관찰조환자재차기출상동보급여중조인혈관내피억제소，3주위1개료정，량조균치료2개료정。재치료과정중，가근거환자치료반응급여상응지지치료。결과치료후，관찰조근기료효위67．64％，현저고우대조조적50．00％（P＜0．05）。치료결속후，량조환자잡씨생활질량평분(KPS평분)균교치료전유소하강，단관찰조하강정도경소（P＜0．05）；치료결속1개월후，량조환자 KPS 평분균교치료전유소승고，차관찰조개선정도경우（P＜0．05）。치료후，관찰조환자적중위진전시간、중위생존기급1년생존솔균현저고우대조조（P＜0．05）。량조환자총불량반응발생솔비교，차이무통계학의의（P＞0．05）。결론중조인혈관내피억제소연합배미곡새치료중만기비소세포폐암적근기료효교호，가현저제고환자생존질량，연지중위진전시간，제고중위생존기급1년생존솔，차미현저증가불량반응발생솔，치득림상추엄。
Objective To discuss the clinical efficacy of human recombinant endostatin combined with pemetrexed in treating middle-late stage non-small cell lung cancer.Methods 68 cases of patients with locally advanced non-small cell lung cancer were randomly divided into control group and observation group,34 cases in each group.Two groups of patients were given pemetrexed chemotherapy,based on this,the observation group was give human recombinant endostatin,3 weeks for 1 course of treatment,two groups of patients were treated for 2 courses.In the process of treatment,corresponding support treatment according to the patient re-sponse was given.Results After treatment,the recent curative effect of observation group was 67.64%,which was higher than 50.00% of control group(P <0.05).KPS score after treatment,two groups of patients was decreased,the drop degree of the observa-tion group was less than the control group,but the group differences were statistically significant(P <0.05);1 month after completion of treatment,two groups of patients′KPS score was increased,the improvement in the observation group was better than that of control group,the differences were statistically significant(P <0.05 ).After treatment,the observation group of patients in the progress of time,the median survival and a year survival rates were significantly higher than that of control group,the differences were statistically significant(P <0.05 ).The total incidence rate of adverse reactions were similar between the two groups and had no statistical differ-ence(P >0.05).Conclusion The recombinant human endostatin combined with pemetrexed in treating locally advanced non-small cell lung cancer in the near future curative effect is good,can significantly improve the quality of survival,tumor in the progress of time,the median survival and a year survival rate,and on the basis of combination treatment does not significantly increase the inci-dence of adverse reactions,which is worthy of clinical promotion.
